VivoSeq
Other

Obese Women

0

Pipeline Programs

0

Active Trials

1

Companies Involved

Obese Women is an early-stage landscape with 0 programs across 1 company. The most active players are Bayer.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

13

clinical trials

Completed10 · 77%
Unknown status2 · 15%
Withdrawn1 · 8%

Trial Activity

13 trials

Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean
Completed··Phase 4·NCT03693599·1,200 enrolled
DPE Technique in Labor Epidural for Morbidly Obese Women
Completed··Phase 4·NCT03074695·141 enrolled
Chiglitazar/Metformin in Non-obese Women With PCOS
Completed·SShengjing Hospital·Phase 2/3·NCT06125587·55 enrolled
US Ovulation Inhibition Study in Obese Women
Completed·Bayer logoBayer·Phase 2·NCT00873483·173 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)